Piperacillin-Tazobactam-induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy

被引：6

作者：

Yusef, Dawood ^{[1
]}

Gonzalez, Blanca E. ^{[2
]}

Foster, Charles B. ^{[2
]}

Goldfarb, Johanna ^{[2
]}

Saracusa, Carla ^{[2
]}

Worley, Sarah ^{[3
]}

Sabella, Camille ^{[2
]}

机构：

[1] Jordan Univ Sci & Technol, Dept Pediat, Irbid, Jordan

[2] Cleveland Clin Childrens, Ctr Pediat Infect Dis, Cleveland, OH USA

[3] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2017年 / 36卷 / 01期

关键词：

piperacillin-tazobactam; adverse drug events; outpatient parenteral antimicrobial therapy; INFECTIOUS-DISEASES SOCIETY; CHILDREN; NEUTROPENIA; AMERICA; FEVER;

D O I：

10.1097/INF.0000000000001351

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report a significantly higher occurrence of adverse events associated with prolonged courses of piperacillin-tazobactam compared with other antibacterial agents used for pediatric outpatient parenteral antimicrobial therapy. These adverse events were characterized by a constellation of clinical findings including fever, hematologic abnormalities and transaminitis. Adverse events related to piperacillin-tazobactam should be considered in patients who develop a febrile illness associated with a prolonged course of therapy.

引用

页码：50 / 52

页数：3

共 10 条

[1]

Bradley JS, 2015, 2015 NELSONS PEDIAT, V2015, P157

[2]

Freifeld AG, 2011, CLIN INFECT DIS, V52, pE56, DOI 10.1093/cid/cir073

[3] Piperacillin-tazobactam:: a β-lactam/β-lactamase inhibitor combination [J].